Last reviewed · How we verify
efavirenz, stavudine extended release, lamivudine
efavirenz, stavudine extended release, lamivudine is a Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved.
Efavirenz, stavudine extended release, and lamivudine is a marketed combination therapy by Bristol-Myers Squibb, positioned in the antiretroviral market. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the lack of recent key trial results to support ongoing efficacy and safety, which may impact market confidence.
At a glance
| Generic name | efavirenz, stavudine extended release, lamivudine |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients (PHASE3)
- DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy (PHASE4)
- Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) (PHASE3)
- Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- efavirenz, stavudine extended release, lamivudine CI brief — competitive landscape report
- efavirenz, stavudine extended release, lamivudine updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI